Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | DHODH | Q02127 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | GMNN | O75496 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | PIM1 | P11309 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.59 |
| ▸ | CCKBR | P32239 | 1/20 | 0.59 |
| ▸ | MC4R | P32245 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | THPO | P40225 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9812326 | 0.88 | GPBAR1 (0.49) | SMN1; SMN2DHODHNPC1GMNNLMNA | |
| SCHEMBL5071947 | 0.83 | NPC1 (0.55) | SMN1; SMN2DHODHNPC1GMNNLMNA | |
| SCHEMBL29791455 | 0.82 | GPBAR1 (0.54) | NPC1CYP3A4CYP2C19RAB9AGPBAR1 | |
| SCHEMBL8808399 | 0.79 | RAB9A (0.51) | SMN1; SMN2DHODHNPC1GMNNLMNA | |
| SCHEMBL20368971 | 0.79 | CYP3A4 (0.51) | SMN1; SMN2DHODHNPC1GMNNLMNA | |
| SCHEMBL9114519 | 0.77 | DHODH (0.64) | SMN1; SMN2DHODHNPC1GMNNLMNA | |
| SCHEMBL27344723 | 0.75 | RAB9A (0.47) | SMN1; SMN2DHODHNPC1GMNNLMNA | |
| Leflunomide SCHEMBL1243495 | 0.74 | RAB9A (1.00) | SMN1; SMN2DHODHNPC1GMNNLMNA | |
| SCHEMBL8822133 | 0.74 | DHODH (0.64) | SMN1; SMN2DHODHNPC1GMNNLMNA | |
| SCHEMBL14359730 | 0.74 | MLYCD (0.51) | SMN1; SMN2DHODHNPC1GMNNLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160024011-A1 | Multi-API Loading Prodrugs | ALKERMES PHARMA IRELAND LTD (IE) | 2016-01-28 | — | — | US | disclosed |
| EP-0527736-B1 | ISOXAZOLE-4-CARBOXAMIDES AND HYDROXYALKYLIDENE-CYANOACETAMIDES, DRUGS CONTAINING THESE COMPOUNDS AND USE OF SUCH DRUGS | HOECHST AG (DE) | 1997-04-16 | — | — | EP | disclosed |
| US-5532259-A | ANTITUMOR | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-07-02 | — | — | US | disclosed |
| US-5494911-A | TREATING LEUKEMIA, SARCOMA, CARCINOMA, LYMPHOMA, SKIN CANCER | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-02-27 | — | — | US | disclosed |
| WO-1991017748-A1 | ISOXAZOLE-4-CARBOXAMIDES AND HYDROXYALKYLIDENE-CYANOACETAMIDES, DRUGS CONTAINING THESE COMPOUNDS AND USE OF SUCH DRUGS | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-11-28 | — | — | WO | disclosed |
| EP-0012435-A2 | Isoxazole derivatives, process for their preparation, medicines containing them and intermediates required in this process | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024011-A1 | Multi-API Loading Prodrugs | AADAC, PAICS, ABCG2 | SMN1; SMN2 1062/4885DHODH 1643/4885NPC1 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.